Skip to main content
Contact Us
Subscribe
E-Edition
43°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Fennec Pharmaceuticals Inc
(NQ:
FENC
)
11.09
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
11.09
Bid (Size)
4.470 (1)
Ask (Size)
12.80 (9)
Prev. Close
11.09
Today's Range
11.09 - 11.09
52wk Range
6.300 - 11.92
Shares Outstanding
26,634,676
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
FENC Stock Earnings: Fennec Pharmaceuticals Misses EPS, Beats Revenue for Q4 2023
March 21, 2024
FENC stock results show that Fennec Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Earnings Scheduled For March 21, 2024
March 21, 2024
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million.
Via
Benzinga
Performance
YTD
-0.31%
-0.31%
1 Month
+21.28%
+21.28%
3 Month
-3.94%
-3.94%
6 Month
+54.82%
+54.82%
1 Year
+31.89%
+31.89%
More News
Read More
Fennec Pharmaceuticals's Earnings Outlook
March 20, 2024
Via
Benzinga
Earnings Scheduled For November 6, 2023
November 06, 2023
Via
Benzinga
Preview: Fennec Pharmaceuticals's Earnings
November 03, 2023
Via
Benzinga
Analyst Ratings for Fennec Pharmaceuticals
June 21, 2023
Via
Benzinga
Recap: Fennec Pharmaceuticals Q1 Earnings
May 11, 2023
Via
Benzinga
Fennec Pharmaceuticals Inc. (NASDAQ: FENC) Highlighted for Surprising Price Action
March 18, 2024
Via
Investor Brand Network
Fennec Pharmaceuticals Inc. (NASDAQ: FENC) Making Surprising Moves in Monday Session
November 06, 2023
Via
Investor Brand Network
Earnings Outlook For Fennec Pharmaceuticals
May 10, 2023
Via
Benzinga
Analyst Ratings for Fennec Pharmaceuticals
April 06, 2023
Via
Benzinga
7 Biotech Stocks Sitting in the Sweet Spot
March 24, 2023
Via
InvestorPlace
US Stocks Open Lower; Dow Dips 250 Points
January 25, 2023
Via
Benzinga
Expert Ratings for Fennec Pharmaceuticals
November 22, 2022
Via
Benzinga
What 4 Analyst Ratings Have To Say About Fennec Pharmaceuticals
November 22, 2022
Via
Benzinga
4 Analysts Have This to Say About Fennec Pharmaceuticals
November 22, 2022
Via
Benzinga
Where Fennec Pharmaceuticals Stands With Analysts
November 22, 2022
Via
Benzinga
Why Stabilis Solutions Shares Jumped Over 71%; Here Are 70 Biggest Movers From Yesterday
September 22, 2022
Via
Benzinga
After Two FDA Rejections, Fennec Pharma Lead Drug Scores US Approval For Chemo-Induced Hearing Loss
September 21, 2022
Via
Benzinga
Why Adamis Pharmaceuticals Is Trading Lower By Around 44%, Here Are 46 Stocks Moving In Wednesday's Mid-Day Session
September 21, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2022
September 07, 2022
Via
Benzinga
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know
August 31, 2022
Via
Benzinga
NASDAQ:FENC Long Term Shareholder Notice: Investigation over Possible Wrongdoing at Fennec Pharmaceuticals Inc.
June 01, 2022
Via
SBWire
U.S. FDA accepts Fennec Pharma's New Drug Application (NDA) Resubmission for PEDMARK
April 27, 2022
Via
Benzinga
NASDAQ:FENC Shareholder Notice: Deadline on April 11, 2022 in Lawsuit Against Fennec Pharmaceuticals Inc.
April 11, 2022
Via
SBWire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.